IL312157A - History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitors - Google Patents
History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitorsInfo
- Publication number
- IL312157A IL312157A IL312157A IL31215724A IL312157A IL 312157 A IL312157 A IL 312157A IL 312157 A IL312157 A IL 312157A IL 31215724 A IL31215724 A IL 31215724A IL 312157 A IL312157 A IL 312157A
- Authority
- IL
- Israel
- Prior art keywords
- dyrk1a
- pyrrolo
- inhibitors
- triazines derivatives
- triazines
- Prior art date
Links
- 101150086683 DYRK1A gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- KGRPHHFLPMPUBB-UHFFFAOYSA-N pyrrolo[2,1-f][1,2,4]triazine Chemical class C1=NC=NN2C=CC=C21 KGRPHHFLPMPUBB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254733P | 2021-10-12 | 2021-10-12 | |
| US202263347757P | 2022-06-01 | 2022-06-01 | |
| PCT/US2022/046416 WO2023064366A1 (en) | 2021-10-12 | 2022-10-12 | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312157A true IL312157A (en) | 2024-06-01 |
Family
ID=84330173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312157A IL312157A (en) | 2021-10-12 | 2022-10-12 | History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12134625B2 (enExample) |
| EP (1) | EP4415816B1 (enExample) |
| JP (1) | JP2024539620A (enExample) |
| KR (1) | KR20240089275A (enExample) |
| AU (1) | AU2022367222A1 (enExample) |
| CA (1) | CA3234831A1 (enExample) |
| IL (1) | IL312157A (enExample) |
| MX (1) | MX2024004552A (enExample) |
| PY (1) | PY2289204A (enExample) |
| TW (1) | TW202322800A (enExample) |
| UY (1) | UY39979A (enExample) |
| WO (1) | WO2023064366A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3249870A1 (en) * | 2022-01-25 | 2023-08-03 | Kinnate Biopharma Inc. | CDK4/6 KINASE INHIBITORS |
| EP4611890A1 (en) * | 2022-11-03 | 2025-09-10 | BioSplice Therapeutics, Inc. | 4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| WO2024211797A1 (en) * | 2023-04-07 | 2024-10-10 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| CN119019402A (zh) * | 2023-05-24 | 2024-11-26 | 中国科学院上海有机化学研究所 | 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途 |
| WO2025024707A1 (en) * | 2023-07-26 | 2025-01-30 | Kinnate Biopharma Inc. | Inhibitors of cdk2/4/6 kinase |
| US20250206746A1 (en) * | 2023-12-22 | 2025-06-26 | Biosplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| US20060264897A1 (en) | 2005-01-24 | 2006-11-23 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| US10730842B2 (en) * | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| FR3041640B1 (fr) | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| RU2020115154A (ru) * | 2017-10-10 | 2021-11-15 | Сирос Фармасьютикалз, Инк. | Производные пирролотриазина и способы ингибирования киназ там |
| EP3759072A4 (en) | 2018-03-01 | 2021-11-03 | The Trustees of Columbia University in the City of New York | COMPOUNDS, COMPOSITIONS AND METHODS FOR RELATING TOXIC STRESS FROM ENDOPLASMIC RETICULUM |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| EP3813826A4 (en) | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR |
| WO2020081689A1 (en) | 2018-10-16 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Azaindole inhibitors of wild-type and mutant forms of lrrk2 |
| US20230000842A1 (en) | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021257863A1 (en) * | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| AU2021313150A1 (en) | 2020-07-20 | 2023-03-16 | Nido Biosciences, Inc. | Indole compounds as androgen receptor modulators |
| PY2289206A (es) | 2021-10-12 | 2023-11-09 | Biosplice Therapeutics Inc | 7h-pirrolo[2,3-d] pirimidinas y preparación y usos de las mismas |
| WO2023064349A1 (en) | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| EP4543886A1 (en) | 2022-06-23 | 2025-04-30 | BioSplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
-
2022
- 2022-10-12 CA CA3234831A patent/CA3234831A1/en active Pending
- 2022-10-12 US US17/964,489 patent/US12134625B2/en active Active
- 2022-10-12 AU AU2022367222A patent/AU2022367222A1/en active Pending
- 2022-10-12 MX MX2024004552A patent/MX2024004552A/es unknown
- 2022-10-12 JP JP2024522052A patent/JP2024539620A/ja active Pending
- 2022-10-12 PY PY202202289204A patent/PY2289204A/es unknown
- 2022-10-12 TW TW111138697A patent/TW202322800A/zh unknown
- 2022-10-12 KR KR1020247014718A patent/KR20240089275A/ko active Pending
- 2022-10-12 WO PCT/US2022/046416 patent/WO2023064366A1/en not_active Ceased
- 2022-10-12 UY UY0001039979A patent/UY39979A/es unknown
- 2022-10-12 EP EP22801289.4A patent/EP4415816B1/en active Active
- 2022-10-12 IL IL312157A patent/IL312157A/en unknown
-
2024
- 2024-08-15 US US18/806,231 patent/US20250171466A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230312605A1 (en) | 2023-10-05 |
| PY2289204A (es) | 2023-12-05 |
| US12134625B2 (en) | 2024-11-05 |
| KR20240089275A (ko) | 2024-06-20 |
| TW202322800A (zh) | 2023-06-16 |
| JP2024539620A (ja) | 2024-10-29 |
| EP4415816B1 (en) | 2026-03-18 |
| US20250171466A1 (en) | 2025-05-29 |
| UY39979A (es) | 2023-04-14 |
| AU2022367222A1 (en) | 2024-05-02 |
| EP4415816A1 (en) | 2024-08-21 |
| CA3234831A1 (en) | 2023-04-20 |
| MX2024004552A (es) | 2024-06-04 |
| WO2023064366A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312157A (en) | History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitors | |
| EP4077328A4 (en) | PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS | |
| IL302820B1 (en) | Tricyclic carboxamide derivatives as PRMT5 inhibitors | |
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| SG10201804791UA (en) | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| IL321144A (en) | History of N-phenyl-pyrazolo[5,1-A]pyridine-3-carboxamide as wild-type C-KIT kinase inhibitors for the treatment of erectile dysfunction | |
| AU2012204982A8 (en) | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | |
| IL288529A (en) | History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy | |
| IL310403A (en) | Converted pyridine derivatives as SARM1 inhibitors | |
| WO2010144499A3 (en) | Urea derivatives as kinase inhibitors | |
| IL306065A (en) | Uracil history as TRPA1 inhibitors | |
| IL319011A (en) | Triazinone derivatives as NLRP3 inhibitors | |
| IL319009A (en) | Triazinone derivatives as NLRP3 inhibitors | |
| NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| HK40115098A (en) | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| IL306008A (en) | Pyrimidine derivatives are useful as LRRK2 kinase inhibitors | |
| WO2014062852A3 (en) | Thiohydantoin derivatives and uses thereof | |
| HK40118483A (en) | Heterocyclic compounds as pi3ka inhibitors | |
| CA3297023A1 (en) | Triazine derivatives as nlrp3 inhibitors | |
| AU2024307670A1 (en) | Triazine derivatives as nlrp3 inhibitors |